EIKN shares rise 10% after the company dosed the first patient in a key registrational trial for its first-line therapy lung cancer treatmen
EIKN shares rise 10% after the company dosed the first patient in a key registrational trial for its first-line therapy lung cancer treatment.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.